(+)-(2R)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide | 1289620-49-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-(2R)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
• 英文别名: (2R)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide；(2R)-N-hydroxy-2-methyl-2-methylsulfonyl-4-(4-phenylphenyl)butanamide
• CAS: 1289620-49-0
• 化学式: C₁₈H₂₁NO₄S
• 分子量: 347.435
• InChiKey: GDYIQUFNICPYHF-GOSISDBHSA-N

物化性质

• 密度：
  1.249±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：34.7mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  (2R)-4-biphenyl-4-yl-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.25h， 以55%的产率得到(+)-(2R)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
  参考文献：
  名称：

  [EN] C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
  [FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE À LIAISON C UTILES COMME AGENTS ANTIBACTÉRIENS

  摘要：

  公开号：

  WO2011045703A3

文献信息

• C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
  申请人：Brown Matthew Frank

  公开号：US20120202777A1

  公开（公告）日：2012-08-09

  The present invention is directed to a new class of hydroxamic acid derivatives of Formula I, wherein the variables G, T, D, L, A, X, R 1 and R 2 are as described hereinabove, and their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G、T、D、L、A、X、R1和R2如上所述，并且它们作为LpxC抑制剂的用途，更具体地用于治疗细菌感染。
• COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT
  申请人：Edmondson Scott D.

  公开号：US20120202819A1

  公开（公告）日：2012-08-09

  Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M 2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

  本文描述了一种改进的治疗过度活跃膀胱的方法，其中该方法包括向需要治疗的患者施用β3肾上腺素能受体激动剂、抗胆碱药物和可选的选择性M2拮抗剂。这种联合治疗提供了更好的疗效和/或减少了副作用。
• C-linked hydroxamic acid derivatives useful as antibacterial agents
  申请人：Brown Matthew Frank

  公开号：US08853258B2

  公开（公告）日：2014-10-07

  The present invention is directed to a new class of hydroxamic acid derivatives of Formula I, wherein the variables G, T, D, L, A, X, R1 and R2 are as described hereinabove, and their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G、T、D、L、A、X、R1和R2如上所述，并且它们作为LpxC抑制剂的用途，更具体地说，它们用于治疗细菌感染。
• Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections
  作者：Matthew F. Brown、Usa Reilly、Joseph A. Abramite、Joel T. Arcari、Robert Oliver、Rose A. Barham、Ye Che、Jinshan Michael Chen、Elizabeth M. Collantes、Seung Won Chung、Charlene Desbonnet、Jonathan Doty、Matthew Doroski、Juntyma J. Engtrakul、Thomas M. Harris、Michael Huband、John D. Knafels、Karen L. Leach、Shenping Liu、Anthony Marfat、Andrea Marra、Eric McElroy、Michael Melnick、Carol A. Menard、Justin I. Montgomery、Lisa Mullins、Mark. C. Noe、John O’Donnell、Joseph Penzien、Mark S. Plummer、Loren M. Price、Veerabahu Shanmugasundaram、Christy Thoma、Daniel P. Uccello、Joseph S. Warmus、Donn G. Wishka

  DOI：10.1021/jm2014748

  日期：2012.1.26

  In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid 1a.
• C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
  申请人：Pfizer Inc.

  公开号：EP2488489A2

  公开（公告）日：2012-08-22